COYA Stock Forecast & Price Target

Coya Therapeutics functions in a promising niche of biotechnology, focusing on the modulation of regulatory T cells to address neurodegenerative, autoimmune, and metabolic diseases, which is underscored by their significant operational milestone of activating Canadian ALS centers to enhance patient recruitment and study oversight. The initiation of the Phase 2 ALSTARS trial for COYA 302 not only represents progress toward assessing the therapy's efficacy in ALS patients but also aligns with the company's strategy to leverage their proprietary Treg therapies amidst growing momentum in the field. Furthermore, the recent milestone payments totaling $8.4 million from Dr. Reddy's Laboratories reflect financial backing and confidence in their ongoing clinical developments, laying a solid foundation for future advancements and potential revenue generation.

Coya Therapeutics Inc is facing a negative outlook primarily due to the potential obsolescence of its therapies as new treatment methods for neurodegenerative and autoimmune diseases are developed, which could diminish its market competitiveness. The company reported a net loss of $2.1 million in the third quarter of 2025, a slight improvement compared to the $4.0 million loss in the same quarter in 2024; however, the increased operational expenses of 35% to $6.0 million raise concerns about financial sustainability. Additionally, there are significant risks associated with the protection of intellectual property, as potential failures in this area could lead to costly legal battles that further threaten the company's financial health.